Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NOVO-114
- Development stage
- Preclinical
- Lead developer
- InnovoTEX
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
NOVO-114 is a preclinical-stage Macrocycle Drug Conjugate (MDC) being developed by InnovoTEX. It utilizes a radionuclide payload conjugated to a tumor-localizing macrocycle scaffold. The therapeutic candidate is designed to enhance tumor selectivity and prolong retention within tumor tissues while minimizing systemic exposure and off-target toxicities. NOVO-114 is currently in the discovery stage of development for the treatment of undisclosed solid tumors.
Beyond the preview
Go deeper on NOVO-114.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NOVO-114.